Maria Leonor Ribeiro

Ms. Maria Leonor Ribeiro

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
MRMaria Leonor Ribeiro
Maria Leonor Ribeiro
VCVânia I.B. Castro
Vânia I.B. Castro
JCJoana Vieira de Castro
Joana Vieira de Castro
RPRicardo A. Pires
Ricardo A. Pires
RRRui M. Reis
Rui M. Reis
Nuno M. NevesNuno M. Neves
Nuno M. Neves
Glioblastoma (GBM) is the most lethal and common malignant primary brain tumor in adults. An important feature that supports GBM aggressiveness is the unique composition of its extracellular matrix (ECM). Particularly, fibronectin plays an important role in cancer cell adhesion, differentiation, proliferation, and chemoresistance. Thus, herein, a hydrogel with mechanical properties compatible with the brain and the ability to disrupt the dynamic and reciprocal interaction between fibronectin and tumor cells was produced. High-molecular-weight hyaluronic acid (HMW-HA) functionalized with the inhibitory fibronectin peptide Arg-Gly-Asp-Ser (RGDS) was used to produce the polymeric matrix. Liposomes encapsulating doxorubicin (DOX) were also included in the hydrogel to kill GBM cells. The resulting hydrogel containing liposomes with therapeutic DOX concentrations presented rheological properties like a healthy brain. In vitro assays demonstrated that unmodified HMW-HA hydrogels only caused GBM cell killing after DOX incorporation. Conversely, RGDS-functionalized hydrogels displayed per se cytotoxicity. As GBM cells produce several proteolytic enzymes capable of disrupting the peptide–HA bond, we selected MMP-2 to illustrate this phenomenon. Therefore, RGDS internalization can induce GBM cell apoptosis. Importantly, RGDS-functionalized hydrogel incorporating DOX efficiently damaged GBM cells without affecting astrocyte viability, proving its safety. Overall, the results demonstrate the potential of the RGDS-functionalized hydrogel to develop safe and effective GBM treatments.

3 June 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
LSLia Santos
Lia Santos
MRMaria Leonor Ribeiro
Maria Leonor Ribeiro
TMTiago Magalhães
Tiago Magalhães
JNJana Berit Nieder
Jana Berit Nieder
CMChristian Maibohm
Christian Maibohm
Lung cancer remains the leading cause of cancer-related mortality, and despite its limited efficacy, and low specificity, chemotherapy is still commonly used as a first-line treatment. Herein, we prepare and characterize poly(lactic-co-glycolic acid) (PLGA) nanoparticles (NPs) for the use as a non-targeted nanocarrier drug delivery system for the chemotherapeutic drug, paclitaxel (PTX). Drug loading capability, mono-dispersity, zeta potential, morphology, and drug release profile were determined for the PLGA NPs. Furthermore, the IC 50 of the loaded nanoparticles was determined to be 20 times lower than the IC 50 value of free PTX in cytotoxic studies in A549 lung cancer cells. The time dependent therapeutic efficacy of both free and encapsulated PTX was assess at several time points in A549 monolayers via label-free multiphoton metabolic imaging based on the fluorescence lifetime of the metabolic cofactor NAD(P)H. Specifically, the significant continuous metabolic shift towards oxidative phosphorylation in cells treated with NPs was correlated with the NPs drug release profile, highlighting the sustained and controlled behavior of the drug delivery system. These findings underscore not only the utility of PLGA NPs as a drug delivery system with enhanced efficacy compared to free drug treatments but also the use of label-free multiphoton fluorescence lifetime imaging microscopy for non-invasive imaging, allowing the tracking of metabolic changes on cellular and subcellular level. Additionally, the presented method is extended to include more complex in vitro models allowing for assessing the cellular bioenergetic response of individual cells in 3D models in real time, paving the way for improved therapeutic strategies against lung cancer.